Saccomano Nicholas A 4

What Happened

• Nicholas A. Saccomano, President & CEO and Director of OnKure Therapeutics (OKUR), sold 86 shares on 2026-03-23 in an open market/private sale. The weighted-average price reported was $4.16 per share (range $3.995–$4.235), for total proceeds of roughly $357.
• This sale was executed automatically to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs), per the issuer’s 2023 RSU Equity Incentive Plan — a routine, non-discretionary tax-withholding sale rather than a voluntary market-timing sale.

Key Details

• Transaction date: 2026-03-23; filing date: 2026-03-24 (filed timely, next-day).
• Shares sold: 86; weighted-average sale price: $4.16; price range across trades: $3.995–$4.235; proceeds ≈ $357.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — sale to cover tax withholding on RSU vesting; F2 — multiple trades, weighted-average price reported (detailed per-trade prices available on request); F3 — securities were RSUs (each RSU converts to one share subject to vesting).
• Transaction code: S (sale); context code: F (tax withholding).

Context

• Tax-withholding sales on RSU vesting are common and generally reflect routine administrative action (to satisfy tax obligations) rather than a directional bet by the insider. The amount here is small (~$357) relative to typical insider transaction thresholds.